#USA #Fremont #Alamar Biosciences #Tod White #Justin McAnear

Alamar Biosciences Expands Leadership Team

Alamar Biosciences, a company pioneering precision proteomics for early disease detection, has recently announced significant changes to its leadership team. This strategic move is aimed at enhancing the company's growth momentum and commitment to innovation and operational efficiency attending the next phase of its evolution.

On October 16, 2025, the Alamar board appointed Tod White, JD, as the new President of Alamar Biosciences. White has been pivotal in shaping the company's trajectory since joining the team. His leadership spans multiple domains, including finance, HR management, investor relations, fundraising, corporate development, and legal affairs. This elevation reflects not only the board's high regard for his capabilities but also their confidence in his vision as Alamar undergoes its next growth chapter. "Tod has been a cornerstone of our leadership team," stated Yuling Luo, founder, Chair, and CEO of Alamar Biosciences. "His ability to guide the company through complex situations and foster collaboration across the organization has been instrumental to our success. This promotion signifies the board's faith in Tod’s vision and leadership as we scale our operations and deepen our impact."

To further bolster its financial leadership, Alamar has welcomed Justin McAnear to the role of Chief Financial Officer (CFO). McAnear brings over 25 years of operational and financial leadership experience across various sectors, significantly influencing 10X Genomics' transition into a publicly traded company in 2019. His tenure as CFO at 10X Genomics spanned over five years. Additionally, he held the position of Vice President of International Finance and Operations at Tesla for more than three years, contributing to key initiatives such as the launch of Model X and Model 3 and the acquisition of Solar City. McAnear's early career also includes roles at Apple and JJ, alongside a distinguished service as a naval officer and aviator for over nine years. "Justin's addition to our team marks an exceptional moment for Alamar," emphasized Luo. "He brings a rare blend of strategic vision, operational discipline, and a profound understanding of scaling complex organizations. I look forward to collaborating with him as we continue to grow and innovate."

Together, White and McAnear complement each other's strengths, positioning Alamar to seize future opportunities effectively. Their combined expertise reinforces the company’s commitment to innovation, integrity, and industry-leading performance.

About Alamar Biosciences, Inc.

Alamar Biosciences is a private medical biotechnology company dedicated to making precision proteomics accessible for the earliest detection of disease. The company's patented NULISA™ platform, along with its ARGO™ HT system, integrates the latest advancements in genomics to achieve unparalleled sensitivity at exceptionally low protein concentrations, surpassing the most sensitive protein detection technologies currently available. For further information, visit alamarbio.com.